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Although antibody-mediated immune mechanisms have been shown to be important in immunity to ASF, it remains unclear what role
virus neutralizing antibodies play in the protective response. Virus neutralizing epitopes have been identified on three viral proteins, p30, p54,
and p72. To evaluate the role(s) of these proteins in protective immunity, pigs were immunized with baculovirus-expressed p30, p54, p72,
and p22 from the pathogenic African swine fever virus (ASFV) isolate Pr4. ASFV specific neutralizing antibodies were detected in test group
animals. Following immunization, animals were challenged with 104 TCID50 of Pr4 virus. In comparison to the control group, test group
animals exhibited a 2-day delay to onset of clinical disease and reduced viremia levels at 2 days postinfection (DPI); however, by 4 DPI, there
was no significant difference between the two groups and all animals in both groups died between 7 and 10 DPI. These results indicate that
neutralizing antibodies to these ASFV proteins are not sufficient for antibody-mediated protection.
D 2004 Elsevier Inc. All rights reserved.Keywords: African swine fever virus; Neutralizing antibodies; Viral proteinsIntroduction
African swine fever (ASF) is a highly lethal hemorrhagic
disease of domestic swine where mortality rates can ap-
proach 100% (Hess, 1982; Maurer et al., 1958). The
causative agent, African swine fever virus (ASFV), is
currently the sole member of the newly named Asfarviridae
and is the only known DNA arbovirus (Dixon et al., 2000).
In sub-Saharan Africa, ASFV is maintained in a sylvatic
cycle among wild swine, warthogs and bush pigs, and
argasid ticks of the genus Ornithodoros. Unlike domestic
swine, ASFV infections of wild swine are asymptomatic
with low viremia titers (Plowright et al., 1969). This large
natural reservoir of virus poses a constant threat to domestic
pig populations worldwide.
There is no vaccine available for ASF. Attempts to
vaccinate animals using infected cell extracts, supernatants
of infected pig peripheral blood leukocytes, purified and
inactivated virions, infected glutaraldehyde-fixed macro-
phages, or detergent-treated infected alveolar macrophages0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.11.011
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E-mail address: jneilan@piadc.ars.usda.gov (J.G. Neilan).failed to induce protective immunity (Coggins, 1974; For-
man et al., 1982; Kihm et al., 1987; Mebus, 1988).
ASF vaccine development is significantly hindered by
large gaps in our knowledge of the virus and the complex
virus–host interactions involved in infection and immunity.
Homologous protective immunity does develop in pigs
surviving viral infection. Pigs surviving acute infection with
moderately virulent or attenuated variants of ASFV develop
long-term resistance to homologous, but rarely to heterolo-
gous, virus challenge (Hamdy and Dardiri, 1984; Ruiz-
Gonzalvo et al., 1981). Pigs immunized with live attenuated
ASF viruses (LAV) containing engineered deletions of
specific ASFV virulence/host range genes were protected
when challenged with homologous parental virus (Lewis et
al., 2000).
Humoral immunity is a significant component of the
protective immune response to ASF. ASFV antibodies are
sufficient to protect pigs from lethal ASFV infection
(Hamdy and Dardiri, 1984; Onisk et al., 1994; Ruiz-Gon-
zalvo et al., 1981). However, antibody-mediated effector
mechanisms associated with the protective response and
viral proteins responsible for inducing the response are
undefined. Neutralizing antibodies have been described for
most viruses and in many cases they have been shown to
play a crucial role in a protective response (Dimmock,
Table 1
Survival, fever response, and viremia of Pr4D9GL-immunized pigs following challenge with Pr4a
Group No. surviving Days to death Fever Viremia
Days to onset
(no. of animals
with fever)
Duration Mean temp. Days to onset
(no. of viremic
animals)
Duration Max titer
(log10 TCID50/ml)
Control (n = 4) 0/4 8.5 F 0.5 3.5 F 0.5 6.5 F 1.5 106.2 F 0.2 4.0 4.5 F 0.3 9.1 F 0.3
Pr4D9GL (n = 4) 4/4 15.0 (2) 5.0 F 0.7 105.7 F 0.5 10.5 F 3.5 (2) 14.0 2.9 F 0.6
a Control and Pr4D9GL immunized pigs were challenged intramuscularly with 104 TCID50 of Pr4 at 42 days post immunization.
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virion proteins p30, p54, and p72 have been described
(Borca et al., 1994; Gomez-Puertas et al., 1996; Zsak et
al., 1993). And, it has been shown that a neutralizing
antibody response to p30 and p54 together provide partial
protection to infection (Barderas et al., 2001; Gomez-Puer-
tas et al., 1998).
Here, using immunization and challenge experiments
with the African ASFV isolate Pr4, we have examined the
role of p30, p54, p72, and p22 in protective immunity.Results
To evaluate homologous protective immunity to the
African ASFV isolate Pr4, pigs were first immunized
intramuscularly with 104 TCID50 of Pr4D9GL, an 9GL
gene deletion mutant of Pr4 that is attenuated in pigs (Lewis
et al., 2000; Zsak et al., unpublished data). Protective
immunity was assessed by challenging immunized animals
intramuscularly with 104 TCID50 of the virulent parental
strain Pr4 at 42 days post immunization. Solid protective
immunity to Pr4 challenge was observed for all Pr4D9GL-
immunized animals. Here, protection was characterized by
100% survival, the absence of clinical disease, a delayed
onset of fever (observed in two of four animals), a delayed
onset of viremia (observed in 2 of 4 animals), and a 106-fold
reduction in maximum viremia titers (Table 1). The level of
protection observed here for Pr4 is comparable to thatFig. 1. Expression of ASFV proteins in Sf1 cells infected with recombinant
baculoviruses expressing: (lane 1) h-galactosidase-control; (lane 2) p72;
(lane 3) p30; (lane 4) p54; and (lane 5) p22. Size markers are shown on the
right in kDa.previously reported for the African isolate Malawi Lil20/1
(Lewis et al., 2000) and the pathogenic European isolate
E75 (Onisk et al., 1994).
To examine the roles of ASFV proteins p30, p54, p72,
and p22 in Pr4 protective immunity, recombinant baculovi-
ruses expressing these proteins were constructed. ASFV
p30, p54, p72, and p22 ORFs were amplified from Pr4
genomic DNA template. PCR products were sequentially
inserted into a TA cloning vector, PCR2.1, and baculovirus
transfer vector, pBlueBac III, and verified by sequence
analysis.
Expression of ASFV proteins was evaluated by im-
munoprecipitation using hyper-immune anti-ASFV swine
serum and 35S-methionine pulse-labeled baculovirus-
infected Sf21 cell extracts (Fig. 1). Specific ASFV
protein bands corresponding to ASFV p72 (lane 2), p30
(lane 3), p54 (lane 4), and p22 (lane 5) were observed. In
the control lane (insect cells were infected with a
recombinant baculovirus expressing h-galactosidase from
the polyhedron promoter), a band corresponding to h-
galactosidase was observed. Results were confirmed by
Western blot and SDS-PAGE gel analyses (data not
shown).
Pigs (n = 6) were immunized with cocktails of the
four baculovirus-expressed ASFV proteins as described.
Sera from these animals were examined for ASFV anti-
bodies using immunoperoxidase, capture ELISA, and
neutralization assays. In peroxidase assays, anti-ASFV
antibodies, with titers ranging from 1:80 to 1:1280 were
observed (Table 2). Capture ELISA titers ranged from
1:1600 to 1:3200 (Table 2). Virus neutralization titersTable 2
Swine antibody responses following immunization with baculovirus-
expressed ASFV structural proteins
Pig no. Serologic assaysa
Immunoperoxidase Indirect ELISA Neutralization
138 1:320 1/3200–1/6400 1/800–1/1600
139 1:1280 1/3200–1/6400 1/800–1/1600
140 1:160–320 1/1600–1/3200 1/800–1/1600
141 1:80 1/1600–1/3200 1/800–1/1600
142 1:320 1/3200–1/6400 1/800–1/1600
143 1:320 1/3200–1/6400 1/1600–1/3200
Hyper-immune >1:1280b 1/3200–1/6400 1/3200–1/6400
a These titers represent the range obtained from three independent assays.
b End point was not determined.
Fig. 2. Western blot analysis of serum from animals immunized with ASFV
proteins, p72, p54, p30, and p22. Lanes 2–7 represent serum from
immunized animals at 14 days following the last booster immunization.
Lane 8, control swine serum. Individual animal numbers are shown below.
Size markers (lane 1) are shown in kDa.
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swine serum (serum from an animal that had survived
multiple Pr4 infections) had a neutralization titer of
1:6400 (Table 2). Qualitative assessment of antibody
levels against individual ASFV proteins was examined
by radio-immunoprecipitation analysis (Fig. 2.). All test
sera contained antibodies to p22, p30, p54, and p72.
Responses to p22, p30, and p54 were relatively consis-
tent among animals. Variability in response to p72 was
observed however it did not correlate with ELISA or
neutralizing titer variability.
To assess the role of antibodies to p30, p54, p72, and p22
for protective immunity, immunized pigs were challenged
with Pr4 (104 TCID50). Clinical signs and viremia were
monitored. Results from this experiment are shown in Table
3. A significant delay in the onset of clinical disease of
approximately 2 days was observed for the immunized
group. Onset of viremia was unchanged and apart from a
transient decrease in virus titer at 2 DPI for the test group,
survival rate and time to death were similar to control group
values.Table 3
Swine fever response and viremia following challenge of p30-, p54-, p72-, and p
Group Number surviving Days to death Fever
Days to onset
Test 0/6 9.2 (0.5)* 4.0 (0.0)
Control 0/4 9.0 (0.0) 2.3 (0.3)
*Means (with standard errors).Discussion
Apart from a brief delay in initial disease onset, immu-
nization of swine with p22, p30, p54, and p72 had no effect
on disease development, progression, nor outcome (Table
3). Notably, immunized animals had anti-ASFV serologic
titers comparable to or higher than those observed for
animals successfully protected (Barderas et al., 2001;
Gomez-Puertas et al., 1998) or titers present in hyper-
immune ASFV swine serum (Table 3). These data indicate
that neutralizing antibodies to these viral proteins are not
sufficient for mediating protection.
Gomez-Puertas et al. (1998) have reported partial protec-
tion for swine immunized with baculovirus-expressed p30
and p54 following challenge with the pathogenic European
ASFV isolate E75. Here, 50% of the animals died and clinical
disease and significant viremias were evident in most of the
survivors. The lack of protection reported here is unlikely to
be due to differences in the ASFV challenge model used in
the two studies. Notably, in both the E75 and Pr4 challenge
models—which differ in virus strains and challenge dose—
solid protection characterized by survival, an absence of
clinical disease (delayed fever in some cases), and delayed
onset and magnitude of viremia is obtained (Onisk et al.,
1994). Virulence of the challenge strains used may in part
account for the differences. Data are available suggesting that
although pathogenic, European ASFV isolates may be more
attenuated and adapted for domestic pigs than African field
isolates (Mebus, 1988; Ordasalvarez and Marcotegui, 1987).
If this is the case, consistent with the results of Gomez-
Puertas et al. (1998), partial protection following challenge
with a more attenuated virus might be expected.
Together, these data indicate that neutralizing antibodies
to these viral proteins are not sufficient to confer protective
immunity to viral challenge. And further, they suggest that
the relative role of this neutralizing antibody response to
antibody-mediated protection may be dependent on the
virulence of the ASFV isolate.
Conceivably ASF antibody-mediated protection may be
a complex event requiring multiple responses (Ruiz-Gon-
zalvo et al., 1996) to many different viral proteins, some
perhaps involving virus neutralization. In the absence of the
whole response, individual contributions of individual pro-
tective antigens are difficult to demonstrate experimentally.
And, it is possible that additional yet to be discovered22-immunized pigs with Pr4
Viremia
Days to onset Mean titer log10 TCID50/ml
2 DPI 4 DPI 7 DPI
2.0 (0.0) 5.6 (0.1) 8.3 (0.3) 8.8 (0.2)
2.0 (0.0) 7.4 (0.3) 8.7 (0.1) 9.3 (0.3)
p30
Forward: 5V-AGAGGTTGAAGATCCATGGTTACCCATT-3V (NcoI)
Reverse: 5V-CTAATAAATCTGGATCCTGCTGCTGCAG-3V (BamHI)
p54
Forward: 5V-CTTATAATATACTGCAGTATGTTGAGTC-3V (PstI)
Reverse: 5V-TTCTTGAGGATCCTTGGAAAGTTGGTCC-3V (BamHI)
p72
Forward: 5V-TATCAGGATCCTTCGCATAAACCGCCA-3V (BamHI)
Reverse: 5V-GGAAGCCCACAGATCTAACCCATTGTG-3V (BglII)
p22
Forward: 5V-CAGAAAGGATCCAATATTATGTAGACC-3V (BamHI)
Reverse: 5V-CGATGCACAATATTATAAGCTTTAAACCG-3V (HindIII)
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ever, it is much more likely that other effector mechanisms
apart from virus neutralization are important for antibody-
mediated protection.
Other in vitro cytolytic effector functions mediated by
anti-ASFV antibody have been described; however, no
significant correlation between complement-dependent an-
tibody lysis and antibody-dependent cell-mediated cytotox-
icity antibody titers in vitro and protective immunity have
been demonstrated (Norley and Wardley, 1982; Norley and
Wardley, 1983). Interestingly, anti-ASFV antibodies have
been shown to have novel inhibitory effects on ASFV
replication (DeTray, 1957; Malmquist, 1963; Mebus,
1988; Onisk et al., 1994; Schlafer et al., 1984a, 1984b).
This phenomenon was first described in macrophage cell
cultures by Malmquist (1963) and later by Coggins et al.
(1968). The continuous presence of convalescent serum (at
nearly undiluted concentrations) protected autologous
buffy-coat cell cultures from infection with homologous
but not heterologous ASFV strains. This monocyte infec-
tion-inhibition (M-II) activity was mediated by the purified
IgG fraction and was effective in inhibiting viral replication
after virus adsorption had occurred (Ruiz-Gonzalvo et al.,
1986a, 1986b). And notably, M-II antibody titers correlated
with protection from challenge (Knudsen et al., 1987; Ruiz-
Gonzalvo et al., 1986b). We are currently assessing the role
of M-II antibodies in protective immunity and identifying
viral proteins that induce them.Materials and methods
Virus strains and cell culture
The pathogenic ASFV isolate Pr4 (Kleiboeker et al.,
1998), the attenuated recombinant Pr4 9GL gene deletion
mutant (Pr4D9GL) (Zsak et al., unpublished data), and
Vero cell culture adapted virus BA71V (kindly provided
by Jose M. Escribano INIA, Madrid, Spain) were used in
these experiments. Insect cell lines SF21 and High Five
(Invitrogen, Carlsbad, CA) were propagated in Grace’s
Insect Media (Invitrogen) and Ex-cell 400 Media (JRH
Biosciences, Inc., Lenexa, KS) supplemented with 5%
fetal bovine serum (FBS) and incubated at 27 jC. Vero
cells were obtained from American Type Culture Collec-
tion (ATCC), propagated in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS) and incubated at 37 jC under 5% CO2.
Primary porcine macrophage cell cultures were prepared
from heparinized swine blood as previously described
(Neilan et al., 1997).
PCR and DNA sequencing analysis
Genes encoding p30, p54, p72, and p22 were amplified,
by PCR, using genomic DNA prepared from PR4. Specificprimers selected for each gene were modified to create
unique restriction sites at the 5V and 3V ends, respectively.
Primer pairs were:PCR was performed for 40 cycles of thermal denatur-
ation (96 jC for 15 s), re-annealing (50 jC for 30 s),
and extension (60 jC for 30 s) with AmpliTaq DNA
polymerase (Perkin-Elmer, Roche, NJ). Amplified prod-
ucts were cloned into the TA cloning vector, pCR2.1
(Invitrogen), and cloned inserts were verified by sequence
analysis using the chain termination method (Sanger et
al., 1977).
Construction of recombinant baculoviruses
Cloned PCR products were digested with appropriate
enzymes and inserted in the multiple cloning site of the
baculovirus transfer vector, pBlueBac III (Invitrogen).
Recombinant pBlueBac III plasmid DNAs were purified
and sequenced to ensure sequence fidelity and correct
orientation for expression. Co-transfection experiments
were performed using a commercial transfection kit
according to the manufacturer’s protocol (Invitrogen).
Recombinant, h-galactosidase-expressing plaques were
selected and plaqued purified three times to homogeneity.
Immunoprecipitation
For detection of ASFV gene expression, recombinant
baculovirus and mock infected insect cells (Sf21) were
labeled with 35S-methionine. Infected cells were lysed in
lysis buffer and incubated with hyper-immune anti-ASFV
swine sera for 1 h. Immune complexes were precipitated
by the addition of protein A-coated Sepharose CL-4B
(Sigma, St. Louis, MO). Immunoprecipitates were washed
four times in lysis buffer, solubilized by boiling in
loading buffer, and analyzed by 10–20% gradient SDS
gel electrophoresis (Novex, San Diego, CA) using auto-
radiography.
For detection of antibodies from immunized pigs,
ASFV-infected and mock-infected swine macrophage or
Vero cell cultures were pulse-labeled with 35S-methionine,
lysed, and incubated with test pig sera as described
above.
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Monospecific antisera from rabbits immunized with
baculovirus-expressed p22, p30, p54, or p72 were combined
and used as capture antibody. The pooled antisera were
diluted 1:400 in a 0.05 M carbonate buffer (pH 9.6) and
allowed to coat Immulon 2 plates overnight at 4 jC. ASFV
antigen was prepared by inoculating roller bottles containing
confluent Vero cells with Ba71V (MOI = 1) and harvesting
when cultures reached 90–100% CPE. Antigen was semi-
purified by centrifugation on 30% and 60% sucrose step
gradients at 15,000  g. Antigen was diluted 1:100 in
blocking buffer (Milk diluent, KPL, Inc, Gaithersburg, MD)
and incubated for 1 h at 37 jC in a humidified chamber.
Plates were washed twice with wash buffer (KPL). Dupli-
cates of swine sera were diluted 1:100–1:4800 in blocking
buffer and incubated for 1 h at 37 jC. Plates were washed
five times with buffer and incubated with peroxidase-la-
beled anti-swine antiserum (KPL) for 1 h at 37 jC. Plates
were washed six times with wash buffer and incubated with
ABTS substrate and peroxide as directed by the manufac-
turer. The reaction was stopped with 1% SDS and the
optical density was read at 405 nm. End-point titers for test
sera were determined as the dilution of serum giving an
optical density reading that was 1.5 greater than the
control sera pool (obtained from animals immunized with
wild-type baculovirus only).
Neutralization test
Serum neutralizing titers were determined using an
infectious focus assay (Zsak et al., 1993). Briefly, heat-
inactivated swine sera (1 h at 56 jC) were diluted (1:5–
1:6400) in RPMI media with 10% heat-inactivated fetal
bovine serum and 0.05% Tween-80. Pr4 stock virus (108
TCID50/ml) was sonicated, spun at 3000 rpm, adjusted to
0.05% Tween-80, and passed through a 0.45-Am filter
(Millipore). Clarified virus, approximately 100 PFU dilut-
ed in RPMI–0.05% Tween-80, combined with swine sera
(at varying 2-fold dilutions), was incubated overnight at
37 jC. The virus was added to macrophages and incubat-
ed overnight at 37 jC. Infected cells were fixed with ice-
cold methanol and processed for immunoperoxidase stain-
ing using 135D4 monoclonal antibody which detects
ASFV protein p72 (Zsak et al., 1993). End-point titers
of ASFV test sera are expressed as dilutions of sera giving
greater than 50% fewer infected cells compared to control
sera obtained from animals immunized with baculovirus
only.
Swine immunization and infection
Four pigs were immunized intramuscularly with 104
TCID50 of Pr4D9GL, a Pr4 9GL gene deletion mutant
attenuated in pigs (Lewis et al., 2000; Zsak et al., unpub-
lished data). Immunized animals were challenged intramus-
J.G. Neilan et al. / Vircularly with 104 TCID50 of parental Pr4 at 42 days post
immunization. Clinical signs of ASF (rectal temperature
greater than or equal to 40 jC, anorexia, lethargy, shivering,
cyanosis, and recumbency) were monitored daily. Blood
samples were collected every other day postinfection (DPI).
Virus titration of blood samples was performed as previ-
ously described (Onisk et al., 1994). Virus titers were
calculated using the method of Spearman–Karber and
expressed as TCID50 (Finney, 1984).
Ten pigs (20–30 kg) were divided into two groups for
protein immunization experiments: the test group (n = 6)
was immunized intramuscularly with a cocktail of recom-
binant baculovirus-infected insect cell extracts containing
p30, p54, p72, and p22, while the control group (n = 4) was
immunized with the parental baculovirus-infected insect cell
extracts. Each animal dose contained 1–2  108 Sf21 cells
or about 200 Ag total protein emulsified in Freund’s com-
plete adjuvant for the primary inoculation and incomplete
adjuvant for additional boosters administered at 4-week
intervals. Fourteen days following the fourth booster immu-
nization, pigs were challenged intramuscularly with 104
TCID50 of ASFV Pr4 and monitored as described above.Acknowledgments
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